Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
MUSTANG BIO INC (MBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.39-4.78%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MBIO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
progress in clinical trials and regulatory approvals | A primary condition in MUSTANG BIO INC's published investment case. The stated target is advance key therapies to late-stage trials or regulatory milestones by end of 2026. | Intact | failure to achieve significant clinical progress or regulatory milestones in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than an established durable compounder. The long-term thesis is in a watch state, with low confidence and recent financial performance well below its industry cohort.
The evidence snapshot gives no valuation measure or clear account of market expectations, so whether MBIO is cheap or expensive versus peers cannot be assessed. The weak results and loss-making status are known concerns, but the expectations gap is unclear.
Management is rated stable, but recent financial performance is weak and earnings are loss-making. Near term, the smaller size and erratic earnings surprises raise the risk of a miss; the snapshot puts that probability at 50%. A stronger healthcare sector backdrop is a potential support, while the reported delisting-rule notice is a material concern.
A guidance cut on the next call would add pressure to the already weak fundamental picture. Continued weakness in jobs data could also weigh on cyclical healthcare names, while stronger results and guidance from sector bellwethers could support sector momentum. The available evidence does not establish how much any of these outcomes would change MBIO’s business outlook.
Over the next 1 to 3 years, the thesis depends on improved company performance and whether sector support can offset high company-specific risk. Evidence is limited and confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
maintain sufficient cash and funding to continue operations |
| A primary condition in MUSTANG BIO INC's published investment case. The stated target is raise enough capital to fund operations through 2027. |
| Under Pressure |
| failure to secure funding leading to operational or listing risks |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
resolve Nasdaq delisting and stabilize stock price | A supporting condition in MUSTANG BIO INC's published investment case. The stated target is bid price above Nasdaq minimum and stock price recovery above 11% drawdown. | Broken | failure to regain Nasdaq compliance or further price decline beyond current drawdown | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-51.50 → $-51.50 · observed estimates
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-07-25 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-07-26 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-07-27 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-07-28 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-07-29 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-07-30 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-07-31 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-01 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-02 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-03 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-04 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-05 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-06 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-07 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-08 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-09 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-10 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-12 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-13 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-14 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-15 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-16 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-17 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-18 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-19 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-20 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-21 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-22 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-23 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-24 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-25 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-26 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-27 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-28 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-29 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-30 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-08-31 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-01 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-02 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-03 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-04 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-05 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-06 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-07 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-08 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-09 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-10 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-11 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-12 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-13 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-14 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-15 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-16 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-17 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-18 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-19 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-20 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-21 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-22 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-23 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-24 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-25 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-26 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-27 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-28 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-29 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-09-30 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-01 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-02 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-03 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-04 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-05 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-06 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-07 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-08 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-09 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-10 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-11 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-12 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-13 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-14 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-15 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-16 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-17 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-18 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-19 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-20 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-21 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-22 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-23 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-24 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-25 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-26 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-27 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-28 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-29 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-30 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-10-31 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-11-01 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-11-02 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-11-03 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-11-04 | $-51.50 | $55,600,000 | 1 / 1 |
| 2026-11-05 | $-51.50 | $55,600,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.